Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.16.3.1 (
ceruloplasmin
)
5,074
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Reelin
is a secreted extracellular matrix protein approximately 410 kDa mol. wt that is reduced in brains of patients with schizophrenia, autism, bipolar disorder and major depression. Recent reports also indicate its near absence in sera of some patients with an autosomal recessive form of lissencephaly. Moreover,
Reelin
is involved not only in normal cortical lamination of the brain during mammalian embryogenesis but is also implicated in cell signaling systems subserving cognition in adult brain. Here, we show that blood levels of
Reelin
and its isoforms are altered in three psychiatric disorders, namely, schizophrenia, bipolar disorder and major depression. The changes include significant increases in 410 kDa
Reelin
moiety of 49% in schizophrenic patients (p < 0.022) of four ethnic compositions (Caucasian, Vietnamese, Hmong and Laotian) and non-significant increases in depressed patients by 34% vs control blood. In contrast, 410 kDa
Reelin
levels decreased by 33% in bipolar blood, albeit non-signficantly, vs. controls. There was a significant increase of 90% (p < 0.0061) in 330 kDa
Reelin
in Caucasian schizophrenics; the depressed value was elevated by 30% vs. control but non-significantly. Again, in contrast, bipolar 330 kDa value decreased by 31% vs control (p < 0.0480). Finally, all 180 kDa
Reelin
values varied minimally in schizophrenics vs controls. In contrast, the 180 kDa
Reelin
values dropped significantly by 49% (p < 0.0117) and 29% (p < 0.0424) in bipolar and depressed patients, respectively, compared with controls. The alterations in blood
Reelin
values appear to be specific since levels of two other blood proteins,
ceruloplasmin
and albumin did not vary significantly between all psychiatric subjects and controls. These findings suggest that blood
Reelin
levels and its isoforms may be used as potential peripheral markers to diagnose presence of several psychiatric disorders and may also serve as targets for future therapeutic interventions.
...
PMID:Altered levels of Reelin and its isoforms in schizophrenia and mood disorders. 1171 58
1. Autism is a severe neurodevelopmental disorder with potential genetic and environmental etiologies. Recent genetic linkage reports and biochemical analysis of postmortem autistic cerebellum point to
Reelin
, an important secretory extracellular protein, as being involved in the pathology of autism. 2. We hypothesized that blood levels of
Reelin
and its isoforms would be altered in autistic twins, and their first degree relatives versus normal controls. 3. We measured blood levels of unprocessed
Reelin
(410 kDa) and its proteolytic cleavage products (Reelins 330 and 180 kDa) as well as albumin and
ceruloplasmin
in 28 autistic individuals, their parents (13 fathers, 13 mothers), 6 normal siblings, and 8 normal controls using SDS-PAGE and western blotting. 4. Results indicated significant reductions in 410 kDa
Reelin
species in autistic twins (-70%, p < 0.01), their fathers (-62%, p < 0.01), their mothers (-72%, p < 0.01), and their phenotypically normal siblings (-70%, p < 0.01) versus controls.
Reelin
330 kDa values did not vary significantly from controls.
Reelin
180 kDa values for parents (fathers -32% p < 0.05 vs. controls, mothers -34%) declined when compared to controls. In contrast autistic
Reelin
180 kDa increased, albeit nonsignificantly versus controls. Albumin and
ceruloplasmin
values for autistics and their first degree relatives did not vary significantly from controls. There were no significant meaningful correlations between
Reelin
, albumin and
ceruloplasmin
levels, age, sex, ADI scores, or age of onset. 5. These results suggest that
Reelin
410 deficiency may be a vulnerability factor in the pathology of autism.
...
PMID:Reduced blood levels of reelin as a vulnerability factor in pathophysiology of autistic disorder. 1236 96